Get started
Author

Peter Thuss-Patience

Observed names: Peter Thuss‐Patience, Peter Thuß-Patience, Thuss-Patience, Peter
Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Humboldt-Universität zu Berlin, Helios Kliniken, Klinikum im Friedrichshain, Freie Universität Berlin, Charité – Universitätsmedizin Berlin
ORCID: 0000-0002-8544-9872
Observed ORCID: 0000-0002-8544-9872
OpenAlex ID: A5112609736
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
2018 · Kohei Shitara, Mustafa Özgüroğlu, et al. · The Lancet · 1,338
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
2016 · Tobias Janowitz, Peter Thuss-Patience, et al. · British Journal of Cancer · 62
PDF
Extravasations of Oxaliplatin
2003 · Albrecht Kretzschmar, Daniel Pink, et al. · Journal of Clinical Oncology · 34
Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma
2026 · Jun Okui, Satoru Matsuda, et al. · British journal of surgery · 7
Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip)
2022 · Beate Rau, Linda Feldbrügge, et al. · Visceral Medicine · 6
PDF
34. Deutscher Krebskongress informativ. innovativ. integrativ. Optimale Versorgung für alle. Berlin, 19.-22. Februar 2020: Abstracts
2020 · Thuss-Patience, Peter, Cho, Byoung Chul, et al. · Oncology Research and Treatment · 6
PDF
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials
2025 · Jun Okui, Satoru Matsuda, et al. · JNCI Journal of the National Cancer Institute · 4
Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial
2024 · Magdalena K. Scheck, Thorsten O. Goetze, et al. · Oncology Research and Treatment · 2
PDF
What Is New in the German S3 Guideline on Gastric Cancer: Diagnosis, Staging, and Treatment
2026 · Markus Moehler, Yvonne Huber, et al. · Oncology Research and Treatment · 1
Guidelines of Onkopedia: What Is New?
2025 · Magdalena K. Scheck, Salah-Eddin Al-Batran, et al. · Oncology Research and Treatment · 1
PDF
OA02.2. Survival Comparison in Patients With Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
2026 · Satoru Matsuda, Jun Okui, et al. · Diseases of the Esophagus
PDF
Medikamentöse Systemtherapie des ösophagealen Plattenepithelkarzinoms
2026 · Peter Thuss-Patience, Anica Loth · best practice onkologie
Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial
2026 · Jurek Hille, Sylvie Lorenzen, et al. · International Journal of Cancer
Systemic chemotherapy including ramucirumab in combination with pressurized intra-peritoneal aerosol chemotherapy (PIPAC) is a safe treatment option for peritoneal metastasis of gastric cancer
2021 · Linda Feldbrügge, Felix Gronau, et al. · European Journal of Surgical Oncology
RAMIRIS
2020 · Sylvie Lorenzen, Thorsten O Goetze, et al. · Forum
Works count: 15
Citation count: 1,446
H-index: 6
I10-index: 3
Year
Topic
Type